1. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
- Author
-
Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, and Bardin PG
- Subjects
- Administration, Oral, Adolescent, Adult, Aminopyridines administration & dosage, Benzamides administration & dosage, Bronchial Hyperreactivity chemically induced, Bronchial Hyperreactivity physiopathology, Bronchial Provocation Tests adverse effects, Cross-Over Studies, Cyclopropanes administration & dosage, Cyclopropanes therapeutic use, Dose-Response Relationship, Drug, Double-Blind Method, Follow-Up Studies, Forced Expiratory Volume drug effects, Humans, Male, Middle Aged, Phosphodiesterase Inhibitors administration & dosage, Pilot Projects, Treatment Outcome, Allergens adverse effects, Aminopyridines therapeutic use, Benzamides therapeutic use, Bronchial Hyperreactivity drug therapy, Phosphodiesterase Inhibitors therapeutic use
- Abstract
Background: Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, is currently in clinical development for the treatment of asthma., Objectives: This pilot study examined the effect of roflumilast on allergen-induced airway hyperresponsiveness (AHR) to histamine challenge and asthmatic response to allergen challenge., Methods: In a randomized, double-blind, 2-period, crossover trial, 13 patients with mild allergic asthma [mean forced expiratory volume in 1 s (FEV(1)) % predicted = 86%] received a single dose of oral roflumilast 1,000 microg or placebo. Patients were administered roflumilast 60 min before allergen challenge, and asthmatic responses were assessed via change in FEV(1)
- Published
- 2007
- Full Text
- View/download PDF